CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on gene-based medicines for serious diseases, announced the proposed election of Briggs Morrison, M.D. to its Board of Directors at the upcoming annual general meeting. CEO Samarth Kulkarni emphasized Dr. Morrison's extensive pharmaceutical industry experience and clinical development expertise as valuable assets for advancing the company's innovative platform and pipeline.
Dr. Morrison, currently the CEO and Board member of Crossbow Therapeutics, Inc., expressed enthusiasm about joining CRISPR Therapeutics. With over 30 years in the pharmaceutical and biotechnology sectors, he has held executive roles at Syndax Pharmaceuticals, AstraZeneca, Pfizer, and Merck. He has overseen clinical development from Phase 1 to approval for several drugs, including Tagrisso®, Imfinzi®, and Lynparza®.
Dr. Morrison also serves on the boards of various biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He holds a B.S. in Biology from Georgetown University and an M.D. from the University of Connecticut.
CRISPR Therapeutics (Nasdaq: CRSP), un'azienda biofarmaceutica focalizzata su medicinali basati su geni per malattie gravi, ha annunciato la proposta di elezione del Dr. Briggs Morrison al suo Consiglio di Amministrazione durante l'imminente assemblea annuale degli azionisti. Il CEO Samarth Kulkarni ha sottolineato l'ampia esperienza del Dr. Morrison nell'industria farmaceutica e la sua competenza nello sviluppo clinico come asset preziosi per far avanzare la piattaforma innovativa e il portafoglio dell'azienda.
Attualmente CEO e membro del Consiglio di Crossbow Therapeutics, Inc., il Dr. Morrison ha espresso entusiasmo per l'opportunità di unirsi a CRISPR Therapeutics. Con oltre 30 anni nei settori farmaceutico e biotecnologico, ha ricoperto ruoli dirigenziali presso Syndax Pharmaceuticals, AstraZeneca, Pfizer e Merck. Ha supervisionato lo sviluppo clinico dalla Fase 1 fino all'approvazione per diversi farmaci, tra cui Tagrisso®, Imfinzi® e Lynparza®.
Il Dr. Morrison è anche membro dei consigli di amministrazione di varie aziende biotecnologiche ed è un Entrepreneur Partner presso MPM BioImpact. Ha conseguito una laurea in Biologia presso la Georgetown University e un M.D. presso l'Università del Connecticut.
CRISPR Therapeutics (Nasdaq: CRSP), una compañía biofarmacéutica centrada en medicamentos basados en genes para enfermedades graves, anunció la propuesta de elección del Dr. Briggs Morrison para su Junta Directiva en la próxima reunión anual de accionistas. El CEO Samarth Kulkarni enfatizó la amplia experiencia del Dr. Morrison en la industria farmacéutica y su pericia en desarrollo clínico como activos valiosos para avanzar en la plataforma innovadora y el portafolio de la empresa.
El Dr. Morrison, actualmente CEO y miembro de la Junta de Crossbow Therapeutics, Inc., expresó su entusiasmo por unirse a CRISPR Therapeutics. Con más de 30 años en los sectores farmacéutico y biotecnológico, ha ocupado roles ejecutivos en Syndax Pharmaceuticals, AstraZeneca, Pfizer y Merck. Ha supervisado el desarrollo clínico desde la Fase 1 hasta la aprobación de varios medicamentos, incluidos Tagrisso®, Imfinzi® y Lynparza®.
El Dr. Morrison también forma parte de las juntas de varias compañías biotecnológicas y es un Socio Emprendedor en MPM BioImpact. Obtuvo una licenciatura en Biología de la Universidad de Georgetown y un M.D. de la Universidad de Connecticut.
CRISPR Therapeutics (Nasdaq: CRSP)는 심각한 질병을 위한 유전자 기반 의약품에 중점을 둔 생명공학 회사로, 오는 연례 총회에서 Briggs Morrison 박사를 이사회에 선출할 것을 제안한다고 발표했습니다. CEO Samarth Kulkarni는 Morrison 박사의 광범위한 제약 산업 경험과 임상 개발 전문성이 회사의 혁신 플랫폼과 파이프라인을 발전시키는 데 소중한 자산이 될 것이라고 강조했습니다.
현재 Crossbow Therapeutics, Inc.의 CEO이자 이사회 회원인 Morrison 박사는 CRISPR Therapeutics에 합류하게 된 것에 대해 기쁨을 표명했습니다. 제약 및 생명공학 분야에서 30년 이상의 경력을 가진 그는 Syndax Pharmaceuticals, AstraZeneca, Pfizer 및 Merck에서 임원 역할을 수행해 왔습니다. 여러 약물의 임상 개발을 1상에서 승인 단계까지 감독했으며, 여기에는 Tagrisso®, Imfinzi® 및 Lynparza®가 포함됩니다.
또한 Morrison 박사는 여러 생명공학 회사의 이사로 활동하고 있으며 MPM BioImpact의 기업가 파트너입니다. 그는 Georgetown University에서 생물학 학사(B.S.)를, University of Connecticut에서 의학 박사(M.D.)를 취득했습니다.
CRISPR Therapeutics (Nasdaq: CRSP), une société biopharmaceutique axée sur les médicaments basés sur les gènes pour des maladies graves, a annoncé la proposition d'élection du Dr Briggs Morrison à son Conseil d'Administration lors de la prochaine assemblée générale annuelle. Le PDG Samarth Kulkarni a souligné l'expérience étendue de Dr Morrison dans l'industrie pharmaceutique et son expertise en développement clinique comme des atouts précieux pour faire avancer la plateforme innovante et le pipeline de l'entreprise.
Dr Morrison, actuellement PDG et membre du Conseil de Crossbow Therapeutics, Inc., a exprimé son enthousiasme pour rejoindre CRISPR Therapeutics. Avec plus de 30 ans d'expérience dans les secteurs pharmaceutique et biotechnologique, il a occupé des postes de direction chez Syndax Pharmaceuticals, AstraZeneca, Pfizer et Merck. Il a supervisé le développement clinique de la Phase 1 jusqu'à l'approbation de plusieurs médicaments, y compris Tagrisso®, Imfinzi® et Lynparza®.
Dr Morrison siège également au conseil d'administration de plusieurs entreprises biotechnologiques et est Entrepreneur Partner chez MPM BioImpact. Il détient une licence en biologie de l'Université de Georgetown et un diplôme de médecine de l'Université du Connecticut.
CRISPR Therapeutics (Nasdaq: CRSP), ein biopharmazeutisches Unternehmen, das sich auf genbasierte Medikamente für schwere Krankheiten konzentriert, hat die vorgeschlagene Wahl von Dr. Briggs Morrison in seinen Vorstand auf der bevorstehenden Jahreshauptversammlung bekannt gegeben. CEO Samarth Kulkarni betonte, dass Dr. Morrisons umfassende Erfahrung in der Pharmaindustrie und seine Expertise in der klinischen Entwicklung wertvolle Vermögenswerte für den Fortschritt der innovativen Plattform und Pipeline des Unternehmens darstellen.
Dr. Morrison ist derzeit CEO und Vorstandsmitglied von Crossbow Therapeutics, Inc. und äußerte seine Begeisterung für den Beitritt zu CRISPR Therapeutics. Mit über 30 Jahren Erfahrung in der pharmazeutischen und biotechnologischen Branche hat er in verschiedenen Führungspositionen bei Syndax Pharmaceuticals, AstraZeneca, Pfizer und Merck gedient. Er hat die klinische Entwicklung von Phase 1 bis zur Genehmigung für mehrere Medikamente, einschließlich Tagrisso®, Imfinzi® und Lynparza®, überwacht.
Dr. Morrison ist außerdem in den Vorständen verschiedener Biotechnologieunternehmen tätig und ist Entrepreneur Partner bei MPM BioImpact. Er hat einen B.Sc. in Biologie von der Georgetown University und einen M.D. von der University of Connecticut.
- Proposed addition of Briggs Morrison to the Board of Directors, bringing extensive pharmaceutical industry experience.
- Dr. Morrison has a track record of overseeing clinical development from Phase 1 to approval for multiple drugs, which could benefit CRISPR Therapeutics' pipeline.
- Potential concerns about continuity and integration with current board and management team.
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be held this year.
“We are excited to welcome Briggs to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. “His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pipeline, with the goal of developing transformative medicines for patients suffering from serious diseases.”
“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR Therapeutics’ vision forward and contribute to its continued success.”
Dr. Morrison currently serves as Chief Executive Officer and as a member of the Board of Directors of Crossbow Therapeutics, Inc. He is trained as a medical oncologist with over 30 years of experience in the pharmaceutical and biotechnology industries, and has held executive roles at Syndax Pharmaceuticals, AstraZeneca PLC, Pfizer Inc., and Merck & Co., Inc. He has overseen the clinical development from Phase 1 through to approval and life cycle management of many approved drugs, including Tagrisso®, Imfinzi® and Lynparza®. Dr. Morrison serves on the Board of Directors of a number of public and private biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He received his B.S. in Biology from Georgetown University and his M.D. from the University of Connecticut.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY™ (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.
CRISPR THERAPEUTICS® standard word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR Special Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the statements made by Drs. Kulkarni and Morrison in this press release as well as statements regarding any or all of the following: (i) CRISPR Therapeutics’ preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release other than to the extent required by law.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4167
rachel.eides@crisprtx.com
FAQ
Who is proposed to join the CRISPR Therapeutics Board of Directors?
What experience does Briggs Morrison bring to CRISPR Therapeutics?
What impact could the appointment of Briggs Morrison have on CRSP stock?
What notable drugs has Briggs Morrison overseen the development of?
When will the election of Briggs Morrison to the CRISPR Therapeutics Board take place?
What roles does Briggs Morrison currently hold?
